Prolonged idiotypic vaccination against follicular lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 47-53

  Inoges, Susana ^a,b   de Cerio, Ascension Lopez Diaz ^a   Zabalegui, Natalia ^a   Soria, Elena ^a   Villanueva, Helena ^a   Panizo, Carlos ^a   Rodriguez Caballero, Arancha ^d   Suarez, Lilia ^d   Pastor, Fernando ^a   Rodriguez Calvillo, Mercedes ^a   Orfao, Alberto ^d   Bendandi, Maurizio ^a,b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Universidad Pública de Navarra   (Spain)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

Boosters; Follicular lymphoma; Idiotype; Vaccination

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN;

ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CANCER IMMUNIZATION; CANCER RELAPSE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HEADACHE; HUMAN; HUMORAL IMMUNITY; INJECTION SITE REACTION; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; CANCER VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 59249088018     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802601122     Document Type: Article

References (18)

1. Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A. and Levy, R. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med, 327, pp. 1209-1215.
2. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A. Pennington, R. et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med, 5, pp. 1171-1177.
3. Inoges, S., Rodriguez-Calvillo, M., Zabalgui, N., Lopez-Diaz de Cerio, A, Villanueva, H. Soria, E. et al. (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst, 98, pp. 1292-1301.
4. Bendandi, M. (2006) Clinical benefit of idiotype vaccines: Too many trials for a clever demonstration?. Rev Recent Clin Trials, 1, pp. 67-74.
5. Summary of MyVax personalized immunotherapy phase 3 clinical trial results.
6. Press release of specified personalized immunotherapy phase 3 clinical trial results.
7. Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P. R. Janakiraman, N. et al. (2006) Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol, 24, pp. 3107-3112.
8. Carroll, W. L., Thielemans, K., Dilley, J. and Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B-cell tumors. J Immunol Methods, 89, pp. 61-72.
9. Inoges, S., Rodriguez-Calvillo, M., Lopez-Diaz de Cerio, A, Zabalegui, N., Perez-Calvo, J. Panizo, C. et al. (2003) Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica, 88, pp. 1438-1440.
10. Rodriguez-Calvillo, M., Inoges, S., Lopez-Diaz de Cerio, A, Zabalegui, N., Villanueva, H. and Bendandi, M. (2004) Variations in 'rescuability' of immunoglobulin molecules from different forms of human lymphoma: implications for antiidiotype vaccine development. Crit Rev Oncol Hematol, 52, pp. 1-7.
11. Bendandi, M. (2008) Aiming at a curative strategy for follicular lymphoma. CA Cancer J Clin, 58, pp. 305-317.
12. Sanchez, M. L., Almeida, J., Vidriales, B., Lopez-Berges, M. C., Garcia-Marcos, M. A. Moro, M. J. et al. (2002) Incidence of phenotypic aberrations in a series of 467 patients with chronic lymphoproliferative disorders: Basis for the design of specific four-color stainings to be used for minimal residual disease. Leukemia, 16, pp. 1460-1469.
13. Neelapu, S. S., Kwak, L. W., Kobrin, C. B., Reynolds, C. W., Janik, J. E. Dunleavy, K. et al. (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med, 11, pp. 986-991.
14. Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M. Syrengelas, A. et al. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood, 89, pp. 3129-3135.
15. Lopez-Diaz de Cerio, A, Zabalegui, N., Rodriguez-Calvillo, M., Inoges, S. and Bendandi, M. (2007) Anti-idiotype antibodies in cancer treatment. Oncogene, 26, pp. 3594-3602.
16. Zhu, D., McCarthy, H., Ottensmeier, C. H., Johnson, P., Hamblin, T. J. and Stevenson, F. K. (2002) Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 99, pp. 2562-2568.
17. Zabalegui, N., Lopez-Diaz de Cerio, A, Inoges, S., Rodriguez-Calvillo, M., Perez-Calvo, J. Hernandez, M. et al. (2004) Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica, 89, pp. 541-546.
18. Radcliffe, C. M., Arnold, J. N., Suter, D. M., Wormald, M. R., Harvey, D. J. Royle, L. et al. (2007) Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem, 282, pp. 7405-7415.